News

SHARE PRINT BACK TO NEWS

Prelude Fertility Expands Network with Pacific Fertility Center in San Francisco

Partnership Enables Prelude to Extend Services and Increase Business Growth with Prominent Fertility Center

NEW YORK - Sept. 25, 2017 /PRNewswire/ -- Today, Prelude Fertility announced the addition of leading San Francisco-based fertility clinic, Pacific Fertility Center® (PFC) to the growing Prelude Network. The network currently includes Reproductive Biology Associates of Atlanta and the nation's largest donor egg bank, My Egg Bank North America. This marks an important step forward in Prelude's strategy to build a national platform, bolstered by the expertise of top-tier fertility centers. It will advance Prelude's mission to educate a generation of women of childbearing age about their fertility and provide them and others with options to achieve family-building goals in a proactive, care-driven and cost-effective way.

PFC was founded in 1999 with a mission of providing a superior experience to infertility patients through advanced technology and innovation. It was established by Eldon Schriock, M.D., Carolyn Givens, M.D., Isabelle Ryan, M.D., Philip Chenette, M.D. and Carl Herbert, M.D., all of whom remain on staff today, continuing to advance this work — now with Prelude. Together with Liyun Li, M.D. the PFC team also created the first independent egg bank in Northern California. Internationally recognized expert, Joseph Conaghan, PhD leads the state-of-the-art PFC laboratory and one of the most highly trained embryology teams in the country.

"We recognize that people seeking fertility services can go to many different centers for treatment. But, like Prelude, we've differentiated ourselves to date with a proven focus on the patient's individual needs, fertility innovation, and a positive experience from beginning to end," said Dr. Eldon Schriock of Pacific Fertility Center. "As part of the Prelude Network we can have an even bigger impact on the future of fertility care. Together, we'll help people achieve their dream of having a healthy child when they are ready."

The World Health Organization ranks infertility as the third most serious disease worldwide, after cancer and cardiovascular disease. This trend is dominated by people over the age of 35, who — due to career, financial pressures, not finding the right partner or other factors — are now struggling to conceive. Prelude's comprehensive fertility services, coupled with knowledgeable and compassionate care, help reduce the emotional stress and high cost associated with infertility challenges. Its commitment to improving fertility awareness, and providing a proactive approach to family building, will help increase each patient's chance of having a healthy baby when they are ready.

Serial entrepreneur Martin Varsavsky created Prelude Fertility, which launched in October 2016 through an investment by New York-based Lee Equity Partners. Varsavsky serves as Prelude's Executive Chairman, and along with CEO Susan Hertzberg and a team of clinical experts, is focused on building the Prelude Network with a group of highly distinguished partner clinics across the US.  

Hertzberg remarked, "Martin's vision for Prelude is to help people understand their reproductive options, optimize the patient experience, and increase their chances of having a healthy baby now or later, when they are ready. Partnering with Pacific Fertility Center is an exciting next step for our company as we bring the Prelude Method to San Franciscoand soon to other markets."

Prelude's comprehensive services include egg freezing, in vitro fertilization (IVF), genetic screening of embryos, and donor egg matching.

The Pacific Fertility Center team has been recognized as being among the "Best Reproductive Endocrinologists" by U.S. News and World Report, and the Bay Area's "Top Doctors" by Castle Connolly, San Francisco Magazine, and Marin Magazine. Each Pacific Fertility Center physician is a Certified Subspecialist in Reproductive Endocrinology and Infertility by the American Board of Obstetrics and Gynecology.

"Prelude is developing a consistent and trustworthy experience nationwide that improves the fertility treatment system," said Lee Equity Partner, Collins Ward. "Integrating Pacific Fertility Center's premier practice is the next step in that commitment and an encouraging sign of Prelude's growth."

For more information about Prelude, visit www.preludefertility.com.

About Prelude 
Prelude is a comprehensive fertility company focused on providing people with the best options for meeting their family-building goals. Using a proactive approach to fertility care, Prelude aims to improve people's chances of having healthy babies when they are ready. Founded in 2016 by serial entrepreneur Martín Varsavsky, Lee Equity Partners, Reproductive Biology Associates and My Egg Bank North America, the company was established to give men and women more reproductive choices and greater control over their biological clocks. By coupling earlier decision making with the latest reproductive science and technology, Prelude can increase the probability of having a healthy baby and decrease the chances of requiring infertility therapy later in life. www.PreludeFertility.com

About Pacific Fertility Center
Pacific Fertility Center is an international destination for male and female fertility treatment and care. It provides an extensive array of fertility treatment options ranging from egg freezing, in vitro fertilization (IVF), and IVF with ovum donor, to cutting-edge laboratory techniques and technology such as introcytoplasmic sperm injection (ICSI), vitrification, and genetic testing of embryos, including comprehensive chromosome screening (CCS) and preimplantation genetic diagnosis (PGD). www.PacificFertilityCenter.com

About Lee Equity Partners, LLC
Lee Equity Partners is a New York–based private equity firm that partners with strong management teams to accelerate growth and build market leading companies. Lee Equity targets equity investments of $50 to $100 million in middle market control buyouts and growth capital financings in companies with enterprise values of $100 million to $500 million that are located primarily in the United States. The firm invests in a range of industries where the team has deep relationships developed over decades, including financial, healthcare and business services, consumer and media. www.LeeEquity.com